To move from the current heterogeneous dataset towards clinically relevant biomarkers and the identification of putative therapeutic targets, recommendations are derived from the limitations of the available studies to increase the future comparability of microbiome studies in PD. In addition, integration of currently available data on the gut microbiome in PD is proposed to identify robust gut microbiome profiles in PD. Furthermore, expansion of the current dataset to atypical parkinsonism cohorts, prodromal and treatment-na¨ıve de novo PD subjects, measurements of fecal microbial concentrations and a multi-omics assessment are required to provideclinically relevant biomarkers and reveal therapeutic targets within the gut microbiome of PD. CLICK TO REVIEW